InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,757.14
(
0.78%
)
US TECH 100
19,639.96
(
1.03%
)
Dow Jones
42,066.93
(
0.65%
)
Brent Oil
75.74
(
0.83%
)
Bitcoin
69,615.98
(
2.65%
)
Post# of 253531
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Rocky3

Send PM Follow Ignore
Followers 22
Posts 885
Boards Moderated 0
Alias Born 07/31/2010

Rocky3

Re: biomaven0 post# 212021

Thursday, 06/22/2017 5:13:59 PM

Thursday, June 22, 2017 5:13:59 PM

Post# of 253531
So a prior report (1/20/17) shows the Pamrevlumab estimates in neoadjuvant pancreatic cancer. They start in 2022 at $60MM, going to $429MM in 2025; but are then reduced to "probability weighted sales" stating at $12MM, going to $85MM.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up